Wyss Institute Awarded Grant from DARPA to Develop Bioinspired Sepsis Therapeutic Device
Date: Sep 28, 2011
Project integrates microsystems engineering, directed evolution, and biomimicry to target bloodstream infection that is a major killer of combat-injured soldiers and intensive care patients
BOSTON -- The Wyss Institute for Biologically Inspired Engineering at Harvard University announced today that it has been awarded a $12.3 million, four-year grant from the Defense Advanced Research Projects Agency (DARPA) to develop a treatment for sepsis, a commonly fatal bloodstream infection. Sepsis is a major cause of injury and death among combat-injured soldiers in the field, as well as patients in hospital intensive care units.
The proposed treatment would involve a miniaturized, dialysis-like device that could rapidly clear the blood of a wide range of pathogens, much as a living human spleen does, without removing normal blood cells, proteins, fluids, or electrolytes. This novel "Spleen-on-a-Chip" would be portable, self-contained, and easily inserted into the peripheral blood vessels of a septic patient or soldier.
The award is part of DARPA's Dialysis Like Therapeutics program, which seeks to develop ways to dramatically decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States each year. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.
"We are very proud to partner with DARPA to pursue a research effort that could potentially transform how we treat patients with sepsis and save lives by quickly cleansing blood free of pathogens while simultaneously treating with antibiotics," says Wyss Institute Founding Director and Principal Investigator on the grant, Donald Ingber, MD, PhD. "This is a tremendous example of how the Wyss Institute works to bring together outstanding faculty members, expert technical staff, interdisciplinary resources, novel technologies and clinical partner institutions, such as Children's Hospital Boston, to bear on critical medical problems."
The project also includes George Church, Ph.D., a Wyss core faculty member and Professor of Genetics at Harvard Medical School; Joanna Aizenberg, Ph.D., a Wyss core faculty member and Professor of Material Sciences at Harvard School of Engineering and Applied Sciences; and Michael Super, Ph.D., a member of the Wyss Advanced Technology Team as key co-investigators.
The Wyss Institute is a division of Harvard University. Operating in collaboration with Harvard schools, Harvard-affiliated hospitals, Boston University, and the University of Massachusetts Medical School, the Wyss Institute conducts broad interdisciplinary research into the principles that living systems use to build, control, and manufacture, and applies these insights to develop novel materials and devices in areas as diverse as architecture, medicine, robotics, manufacturing, and the environment.
Researchers plan to incorporate several of the Institute's novel technologies in the proposed sepsis dialysis device. The sepsis therapeutic device will leverage recent Wyss Institute advances in organ-on-chip technologies in which key microstructural features of complex organs, such as the spleen, are replicated in microfluidic circuits using microfabrication techniques.
Also key to the technology is the use of magnetic nano- and micro-particles coated with a human opsonin--a key component of the body's innate immune response--that will remove pathogens from flowing human blood using magnetic forces. The opsonin is being genetically engineered to improve its already broad pathogen binding capacity using directed evolution strategies developed at the Institute.
In addition, the sepsis therapeutic device will incorporate a "super" slippery surface that was developed by Institute researchers as a novel material to prevent the adhesion of ice, crude oil, or even dirt. This technology, which is modeled after the slippery surfaces of carnivorous plants that trap insects sliding into the digestive juices of the plant, will be modified to prevent blood clot formation so that patients will not need to be treated with anti-coagulants, such as heparin, when attached to the sepsis therapeutic device.
For more information, contact:
About the Wyss Institute for Biologically Inspired Engineering at Harvard University
The Wyss Institute for Biologically Inspired Engineering at Harvard University (http://wyss.harvard.edu) uses Nature's design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world. Working as an alliance among Harvard's Schools of Medicine, Engineering, and Arts & Sciences, and in partnership with Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Children's Hospital Boston, Dana Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, and Boston University, the Institute crosses disciplinary and institutional barriers to engage in high-risk research that leads to transformative technological breakthroughs. By emulating Nature's principles for self-organizing and self-regulating, Wyss researchers are developing innovative new engineering solutions for healthcare, energy, architecture, robotics, and manufacturing. These technologies are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances, and new start-ups.